Pharmacologic Management of Interstitial Cystitis/Bladder Pain Syndrome

Urol Clin North Am. 2022 May;49(2):273-282. doi: 10.1016/j.ucl.2022.01.003.ABSTRACTInterstitial cystitis/bladder pain syndrome (IC/BPS) is defined as persistent or chronic discomfort perceived to be related to the urinary bladder accompanied by urinary urgency or frequency. Pharmacotherapies used to treat IC/BPS include oral and intravesical agents. Oral therapies include amitriptyline, hydroxyzine, cyclosporine A, and pentosan polysulfate sodium (PPS), although the recent finding of pigmented maculopathy with chronic PPS is very concerning and must be discussed with patients, many of whom will choose to either come off this medicine or not even start it. Certolizumab pegol is a pharmacologic therapy that is currently in clinical development for treatment of IC/BPS symptoms.PMID:35428433 | DOI:10.1016/j.ucl.2022.01.003
Source: The Urologic Clinics of North America - Category: Urology & Nephrology Authors: Source Type: research